PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients
A Prospective, Multicentric, Randomized, Double Blind, Parallel, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Acute Ischemic Stroke
Sponsor: Pharmazz, Inc.
This PHASE2 trial investigates Acute Stroke and Cerebral Ischemia and is currently completed. Pharmazz, Inc. leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE2
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pharmazz, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .